PR Newswire - Ascletis Announces Initiation of Global Phase III ...
-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight across two pivotal trials in the U.S., Eu...
Read More


ภาษาไทย
English